Ann: OncoSil achieves first commercial sale, page-29

Thanks for this Wedgy. I think the basic issue is this. We don’t know what the market is expecting from Oncosil to make the rerate.

Does the market expect hundreds of sales of the Oncosil device before it decides to rerate this company? And when I say rerate, I don’t mean the company trades at 20 cents for 2 minutes before all the selling starts to drive the price down again.

What does the market want? Until we know the answer to that I just don’t see how what will lead to a sustained rerate of this company. So far, everything the Company has done and announced has had a very small effect on the share price.

Im also curious as to why the bar for Oncosil has Ben set higher by the market compared with other bio tech stocks? There are plenty of drug/bio tech spec stocks that do not have any regulatory approval from any jurisdiction. There are many examples of bio tech stocks that have small Phase 1 single arm trials that ha e bounced very very hard on only modest data. Why is Oncosil singled out? Again, why is the bar set at a much higher level for Oncosil???